Danaher Diagnostics — Revenue increased by 6.7% to $2.46B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 4.2%, from $2.36B to $2.46B. Over 3 years (FY 2021 to FY 2024), Diagnostics — Revenue shows relatively stable performance with a -0.2% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates growing market adoption of diagnostic products or successful pricing strategies, while a decrease may signal market saturation, increased competition, or a decline in demand for diagnostic testing.
This metric represents the total gross revenue generated by the Diagnostics business segment from the sale of scientific...
This is equivalent to 'Segment Revenue' reported by life sciences and medical technology peers, typically compared against industry-standard growth rates for the diagnostics sector.
dhr_segment_diagnostics_revenue_from_contract_with_customer_excluding_assessed_tax| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.34B | $2.45B | $2.88B | $2.64B | $2.56B | $2.68B | $2.97B | $2.38B | $2.23B | $2.25B | $2.72B | $2.53B | $2.26B | $2.36B | $2.64B | $2.45B | $2.31B | $2.46B |
| QoQ Change | — | +4.8% | +17.6% | -8.2% | -3.1% | +4.6% | +10.7% | -19.9% | -6.1% | +1.0% | +20.5% | -7.0% | -10.6% | +4.6% | +11.6% | -7.1% | -5.7% | +6.7% |
| YoY Change | — | — | — | — | +9.6% | +9.4% | +2.9% | -10.1% | -12.9% | -15.9% | -8.4% | +6.4% | +1.3% | +4.8% | -2.9% | -3.1% | +2.2% | +4.2% |
We use cookies for analytics. See our Privacy and Cookie Policy.